JP2014509298A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509298A5
JP2014509298A5 JP2013539024A JP2013539024A JP2014509298A5 JP 2014509298 A5 JP2014509298 A5 JP 2014509298A5 JP 2013539024 A JP2013539024 A JP 2013539024A JP 2013539024 A JP2013539024 A JP 2013539024A JP 2014509298 A5 JP2014509298 A5 JP 2014509298A5
Authority
JP
Japan
Prior art keywords
optionally substituted
methyl
substituted
pyrazino
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2012/055489 external-priority patent/WO2012115286A1/en
Publication of JP2014509298A publication Critical patent/JP2014509298A/ja
Publication of JP2014509298A5 publication Critical patent/JP2014509298A5/ja
Pending legal-status Critical Current

Links

JP2013539024A 2011-02-25 2012-02-27 アルファへリックスミメティック及びその関連の方法 Pending JP2014509298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446801P 2011-02-25 2011-02-25
US61/446,801 2011-02-25
PCT/JP2012/055489 WO2012115286A1 (en) 2011-02-25 2012-02-27 Alpha helix mimetics and methods relating thereto

Publications (2)

Publication Number Publication Date
JP2014509298A JP2014509298A (ja) 2014-04-17
JP2014509298A5 true JP2014509298A5 (enExample) 2015-05-07

Family

ID=45878996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539024A Pending JP2014509298A (ja) 2011-02-25 2012-02-27 アルファへリックスミメティック及びその関連の方法

Country Status (5)

Country Link
US (1) US20140051706A1 (enExample)
EP (1) EP2678341A1 (enExample)
JP (1) JP2014509298A (enExample)
CN (1) CN103517904A (enExample)
WO (1) WO2012115286A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102168006B1 (ko) * 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
CA2817975C (en) * 2010-11-16 2020-03-31 Michael Kahn Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
BR112014008360A2 (pt) * 2011-10-07 2017-04-25 Univ Southern California cbp/catenina antagonistas para melhorar divisão assimétrica de células-tronco somáticas
JP2015534942A (ja) * 2012-10-19 2015-12-07 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
US20150274751A1 (en) * 2012-10-19 2015-10-01 Prism Pharma Co., Ltd. Treatment of scleroderma using an inhibitor of cbp/catenin
CN105163760B (zh) 2012-12-12 2018-01-26 株式会社棱镜制药 肝纤维化的预防或治疗试剂
JP6507336B2 (ja) * 2013-10-18 2019-05-08 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ Ｃｂｐ／カテニン阻害剤を用いる肝線維症の治療
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
BR112017027227B1 (pt) * 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX2017015257A (es) 2015-06-23 2018-02-19 Eisai R&D Man Co Ltd Cristal de (6s, 9as)-n-bencil-8-({6-[3-(4-etilpiperazin-1-il)azeti din-1-il]piridin-2-il}metil)-6-(2-(fluoruro-4-hidroxibencil)-4,7- dioxo-2-prop-2-en-1-il)hexahidro-2h-pirazino[2,1-c] [1,2,4]triazon-1-(6h)-carboxamida.
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
CN108026104B (zh) * 2015-09-18 2021-06-18 国立大学法人鸟取大学 利用低分子化合物的癌及纤维化的抑制和再生促进的效果
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
US20220409724A1 (en) 2019-10-29 2022-12-29 Eisai R&D Management Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
KR20220151178A (ko) 2020-03-12 2022-11-14 3＋2 파마, 엘엘씨 Cbp/카테닌 신호전달 경로 억제제 및 그것의 용도
US12486275B2 (en) 2020-03-12 2025-12-02 City Of Hope Substituted pyrazino[2,1-c][1,2,4]triazines as Wnt/CBP/catenin signaling pathway inhibitors
EP4182317A4 (en) * 2020-07-16 2024-08-14 PRISM BioLab Co., Ltd. NEW HETEROCYCLIC COMPOUNDS
CN116925081A (zh) * 2022-04-11 2023-10-24 中国科学院上海药物研究所 一种环肽类化合物及其应用
TW202408503A (zh) * 2022-05-04 2024-03-01 美商雅斯娜製藥公司 治療纖維化之方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1994003494A1 (en) 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of reverse turns and peptides containing the same
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6117445A (en) * 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7087078B2 (en) 2000-11-21 2006-08-08 Schering Ag Tubular vascular implants (stents) and methods for producing the same
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ES2310215T3 (es) * 2001-10-12 2009-01-01 Choongwae Pharma Corporation Estructuras mimeticas de giro inverso y metodo relacionado.
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
RU2383547C2 (ru) * 2003-08-28 2010-03-10 Чоонгвае Фарма Корпорейшн Модуляция бета-катенин/tcf-активируемой транскрипции
WO2006030217A2 (en) * 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
US20080009500A1 (en) 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
JP5536336B2 (ja) 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
BRPI0911383B1 (pt) * 2008-06-06 2021-08-31 Prism Biolab Corporation Composto, composição farmacêutica, uso do referido composto, agentes para tratar ou prevenir câncer, fibrose, restenose associada com angioplastia, doença renal policística, doença de angiogênese aberrante, complexo de esclerose tuberosa (tsc) tumor associado com kshv, perda de cabelo, e doença de alzheimer, e processo para preparar o referido composto
JP5545573B2 (ja) 2008-10-14 2014-07-09 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ アルファへリックスミメティック及び関連の方法
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
CA2758904C (en) * 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
EP2427451B1 (en) 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto

Similar Documents

Publication Publication Date Title
US10766914B2 (en) DNA alkylating agents
EP1797068B1 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
JP2023500395A5 (enExample)
JP2008505117A5 (enExample)
JP2013545810A5 (enExample)
JP2020535168A5 (enExample)
CN115996727B (zh) 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体
JP2010280684A5 (enExample)
JP2005516986A5 (enExample)
HRP20151336T1 (hr) Tetrahidroizokinolin-1-on derivat ili njegova sol
US20080064878A1 (en) Process for producing 1-pyridin-4-yl-indoles
WO2017191650A1 (en) Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
JP2014521620A5 (enExample)
JP2011500796A (ja) 新規前駆体
HU199418B (en) Process for producing new, substituted anilide derivatives
JP2005508292A5 (enExample)
JP2012509262A5 (enExample)
US10202401B2 (en) Process for making tetracyclic heterocycle compounds
RU2003131966A (ru) Производные 4-(фенил-(пиперидин-4-ил)-амино)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
JP2005508290A5 (enExample)
CN107848968A (zh) 从乙醛酸制备内酰胺的方法
JP2005507372A5 (enExample)
JP2005514422A5 (enExample)
JP2007519685A5 (enExample)
MX2013011253A (es) Derivados de 3-ureidoisoquinolin-8-ilo.